BioAffinity Technologies Financials
| BIAFW Stock | USD 0.57 0.13 18.57% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | 1.7674 |
|
|
Investors should never underestimate BioAffinity Technologies' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor BioAffinity Technologies' cash flow, debt, and profitability to make informed and accurate decisions about investing in bioAffinity Technologies Warrant.
Net Income |
|
BioAffinity | Select Account or Indicator |
Understanding current and past BioAffinity Technologies Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BioAffinity Technologies' financial statements are interrelated, with each one affecting the others. For example, an increase in BioAffinity Technologies' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in BioAffinity Technologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of bioAffinity Technologies Warrant. Check BioAffinity Technologies' Beneish M Score to see the likelihood of BioAffinity Technologies' management manipulating its earnings.
BioAffinity Technologies Stock Summary
BioAffinity Technologies competes with BioAffinity Technologies,. bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company was founded in 2014 and is based in San Antonio, Texas. Bioaffinity Technologies operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 09076W117 |
| Location | Texas; U.S.A |
| Business Address | 22211 West Interstate |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.bioaffinitytech.com |
| Phone | 210 698 5334 |
| Currency | USD - US Dollar |
BioAffinity Technologies Key Financial Ratios
| Return On Equity | -1.52 | ||||
| Profit Margin | (1.19) % | ||||
| Operating Margin | (0.87) % | ||||
| Revenue | 2.53 M | ||||
| EBITDA | (7.63 M) |
BioAffinity Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioAffinity Technologies's current stock value. Our valuation model uses many indicators to compare BioAffinity Technologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioAffinity Technologies competition to find correlations between indicators driving BioAffinity Technologies's intrinsic value. More Info.bioAffinity Technologies Warrant is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At this time, BioAffinity Technologies' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value BioAffinity Technologies by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.BioAffinity Technologies Systematic Risk
BioAffinity Technologies' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BioAffinity Technologies volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on BioAffinity Technologies correlated with the market. If Beta is less than 0 BioAffinity Technologies generally moves in the opposite direction as compared to the market. If BioAffinity Technologies Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BioAffinity Technologies is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BioAffinity Technologies is generally in the same direction as the market. If Beta > 1 BioAffinity Technologies moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as BioAffinity Technologies is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of BioAffinity has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if BioAffinity Technologies' financials are consistent with your investment objective using the following steps:- Review BioAffinity Technologies' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand BioAffinity Technologies' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare BioAffinity Technologies' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if BioAffinity Technologies' stock is overvalued or undervalued.
Today, most investors in BioAffinity Technologies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BioAffinity Technologies' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of BioAffinity Technologies growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
BioAffinity Technologies November 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of BioAffinity Technologies help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of bioAffinity Technologies Warrant. We use our internally-developed statistical techniques to arrive at the intrinsic value of bioAffinity Technologies Warrant based on widely used predictive technical indicators. In general, we focus on analyzing BioAffinity Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BioAffinity Technologies's daily price indicators and compare them against related drivers.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 96.67 | |||
| Value At Risk | (26.44) | |||
| Potential Upside | 28.21 |
Additional Tools for BioAffinity Stock Analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.